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Abstract
Background: Amiodarone is an antiarrhythmic drug that is frequently used to control atrial 
fibrillation (AF). Many patients with AF are afraid of the risk of ablation and take amiodar-
one, some patients develop amiodarone-induced thyrotoxicosis (AIT). The purpose of the study 
was to investigate the safety and efficacy of early radiofrequency catheter ablation in patients 
with paroxysmal AF complicated with AIT.
Methods: From the 146 consecutive patients with paroxysmal AF who had been treated with 
amiodarone and underwent 3-dimensional mapping system guided circumferential pulmonary 
vein isolation (PVI) at our center from January 2013 to June 2014, 20 had developed AIT. 
Thirty controls with normal thyroid function and matched for baseline characteristics were 
selected.
Results: Pulmonary vein isolation was completed in all patients without serious complica-
tions and with similar procedural (170.60 ± 14.80 vs. 158.18 ± 9.06 min; p = 0.062) and 
X-ray exposure (16.48 ± 2.15 vs. 15.36 ± 1.57 min; p = 0.058) time in AIT vs. control 
groups; however, upon coronary sinus catheter pacing (from 300 ms to 200 ms) after intrave-
nous isoproterenol administration 30 min post PVI, rates of induction of AF (35% vs. 3.33%;  
p = 0.005) and of non-pulmonary vein-related atrial tachyarrhythmias (50% vs. 6.67%; p = 0.01)  
were higher, while those for atrial flutter (15% vs. 3.33%; p = 0.17) and atrial tachycardia 
(15% vs. 6.67%; p = 0.31) were similar, as was the recovery of conduction of pulmonary 
vein potential (15% vs. 30%; p = 0.191). In AIT vs. control group, atrial tachyarrhythmia 
recurrence rate was higher at 3 months (45% vs. 16.67%, p = 0.032) but not between 3 and  
12 months (30% vs. 23.33%; p = 0.418) follow-up.
Conclusions: Early catheter ablation for paroxysmal AF in patients with AIT appeared safe 
and effective albeit with higher atrial tachyarrhythmia recurrence rate up to 3 months but not 
beyond 12 months after PVI relative to controls. (Cardiol J 2016; 23, 4: 416–421)
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Amiodarone is frequently used to control atrial 
fibrillation (AF) — the most common arrhythmia 
[1, 2]. Because each amiodarone molecule contains 
two iodine atoms with about 10% dissociating into 
free iodine [3], long-term use of amiodarone may 
lead to abnormal thyroid function in 15–20% of 
patients [4], seriously impairing further drug treat-
ment for AF. Although paroxysmal AF refractory 
to oral antiarrhythmic drugs is a class I indication 
of catheter ablation now commonly used for main-
tenance of sinus rhythm [5], studies are lacking on 
its safety and efficacy in patients with frequent and 
symptomatically intolerable paroxysmal AF com-
plicated with amiodarone-induced thyrotoxicosis 
(AIT), which is the subject of the present study.
Methods
Case selection
From 146 consecutive patients with parox-
ysmal AF as per the 2014 American Heart As-
sociation/American College of Cardiology/Heart 
Rhythm Society (AHA/ACC/HRS) guideline who 
underwent ablation at the Affiliated Hospital of 
Qingdao University from January 2013 to June 
2014, 20 (11 males/9 females; mean age 63.65 ± 
± 8.91 years) with frequent and symptomatically 
intolerable paroxysmal AF complicated with AIT 
were selected as the AIT group, while other 30 
(17 males/13 females; mean age 60.67 ± 8.54 years) 
who also received oral amiodarone but continued 
to have normal thyroid function were randomly 
selected as the control group. AIT was diagnosed 
in patients who had normal thyroid function and 
after taking amiodarone had a thyroid stimulating 
hormone (TSH) level < 0.27, free thyroxine (FT4) 
level > 22, and/or free triiodothyronine (FT3) 
level > 6.8 (normal values, TSH: 0.27~4.2 IU/mL; 
FT4: 12.0~22.0 pmol/L; FT3: 3.10~6.80 pmol/L) 
[6]. Patients with any of the following conditions 
were excluded from the AIT group: AF found at 
the same time or after thyrotoxicosis occurrence; 
evidence of organic thyroid disease in thyroid 
ultrasound; presence of antithyroid peroxidase 
(ATPO) antibody and anti-thyroglobulin antibody 
(TG-Ab); persistent AF; structural heart diseases, 
such as valvular heart disease and congenital heart 
disease; and presence of left atrial thrombus in 
transesophageal echocardiography. Before taking 
amiodarone, all patients underwent laboratory 
testing for FT3, FT4, TSH, ATPO, TG-Ab, and 
thyroid ultrasound; while on amiodarone, thyroid 
function was checked every 3 months; amiodar-
one was withdrawn as soon as thyrotoxicosis was 
found, and catheter ablation was planned; all pa-
tients (including AIT and control groups) stopped 
amiodarone and received pulmonary vein isolation 
(PVI) in 3 days; 4 patients with severe thyrotoxico-
sis received methimazole before ablation and the 
other 16 patients in AIT group did not receive any 
treatment. Before circumferential pulmonary vein 
isolation (CPVI) all patients: underwent laboratory 
testing for FT3, FT4, TSH, ATPO, and TG-Ab 48 h 
pre procedure; received the anticoagulant warfarin, 
which was not stopped before PVI if the interna-
tional normalized ratio (INR) was between 2 and 3; 
and were assessed 24 h pre procedure with es-
ophageal ultrasonography to exclude left atrial 
thrombus.
All the patients had signed a general written 
informed consent. Ethical approval was given by 
the medical Ethics Committee of the Affiliated 
Hospital of Qingdao University. The study protocol 
conformed to the ethical guidelines of the 1975 
Declaration of Helsinki.
Mapping and ablation
After left subclavian vein puncture, a 10-elec-
trode electrophysiology catheter was placed in the 
coronary sinus (CS); after 2 atrial septal punctures, 
two 8.5 F Swartz long sheaths (SL1) were placed in 
the left atrium; changes in pulmonary vein poten-
tial were recorded with a LASSO catheter; under 
the guidance of the Carto system, a 3.5 mm ablation 
catheter (Navi-Star ThermoCool, Biosense-Web-
ster, USA) was used for left atrial reconstruction 
and CPVI of the bilateral pulmonary veins; at the 
anterior wall, the discharge energy was 35 W; at 
the top and rear walls, the discharge energy was 
30 W; at each ablation point, the discharge lasted 
20 s or the potential was decreased by 80%; and 
the 2-way bilateral PVI was performed as previ-
ously published [7, 8]. After CPVI, the patient was 
observed for 30 min; isoproterenol via intravenous 
drip then was given to increase the heart rate up 
to 120 bpm. Burst artial pacing was performed 
from CS at a circle length from 300 ms to 200 ms 
to observe whether there was atrial tachycardia, 
atrial flutter, or AF episodes, and whether there oc-
curred recovery of conduction (RoC) of pulmonary 
vein potential.
Postoperative care and follow-up
After catheter ablation, oral warfarin was 
prescribed for at least 3 months, with dose ad-
justment to maintain the INR between 2 and 3. 
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Anticoagulation was extended beyond 3 months 
if AF relapsed. After PVI, none of the patients 
received any antiarrhythmic drugs. For patients 
in the AIT group with severe thyrotoxicosis, upon 
consultation with endocrinologists, methimazole 
was given. The following parameters were cap-
tured: (1) Perioperative complications such as 
cardiac tamponade, embolization, and hematoma; 
(2) Operation time and X-ray exposure time; 
(3) Whether arrhythmia was induced and whether 
there was RoC of pulmonary vein potential after 
isoproterenol administration; (4) The recurrence 
rate of atrial tachyarrhythmia after PVI: surface 
electrocardiogram (ECG) and dynamic ECG were 
recorded at each month during 12-month follow-
up or at the time the patient perceived recurrence 
to determine if it was symptomatic AF, typical 
atrial flutter, or other atrial tachyarrhythmia. AF 
was defined according to 2014 AHA/ACC/HRS 
guidelines. We have defined typical atrial flutter 
as cavotricuspid isthmus-dependent atrial flutter, 
atrial rate 250–350/min. Other atrial tachyarrhyth-
mia was defined as atypical atrial flutter or atrial 
tachycardia. The former refers to non-cavotricuspid 
isthmus-dependent atrial flutter, atrial rate 250– 
–350/min; the latter refers to atrial tachyarrhythmia 
with atrial rate 150–250/min, whose mechanism is 
reentrant or focal. Recurrence could be defined if 
a monitored episode of atrial arrhythmia lasted over 
30 s. If the recurrence occurred within 3 months 
after PVI, it was defined as early recurrence and if 
beyond 3 months as late recurrence [9].
Statistical analysis
All the continuous variables are expressed as 
mean ± standard deviation and were compared with 
single factor analysis of variance, while categorical 
variables are expressed as number and percentage 
and were compared using the c2 test. Statistical 
analyses were performed using SPSS19.0 statisti-
cal software. P < 0.05 was considered statistically 
significant.
Results
Distribution of baseline sociodemographic 
and clinical characteristics, including gender, age, 
left atrial dimension, AF duration, and procedural 
characteristics (Table 1).
In the AIT group, isoproterenol infusion 30 min 
after PVI induced: 1) AF in 7 (35%) cases: 3 from the 
superior vena cava (SVC) terminated after SVC iso-
lation [10], 2 were associated with RoC of pulmonary 
vein conduction, and were terminated by ablation 
at areas with RoC along the PVI ablation line, 
and 2 were neither associated with the SVC nor 
with RoC of pulmonary vein conduction, and were 
treated with electrical cardioversion; 2) Atypical 
atrial flutter or atrial tachycardia in 3 (15%) cases: 
1 left atrial roof-dependent macroreentrant flutter, 
which was terminated by linear ablation at the left 
atrial roof, validated by 2-way block of atrial top 
line [11, 12]; 1 mitral isthmus-dependent macro-
reentrant flutter, which was terminated by linear 
ablation at the mitral isthmus, with the ablation 
being continued until there was 2-way block of 
the mitral isthmus line [11, 12]; and 1 associated 
with atrial-pulmonary vein potential conduction 
gap, which was terminated by gap ablation along 
the PVI ablation line; 3) Typical atrial flutter in 
3 (15%) cases, all tricuspid isthmus-dependent 
which were treated with tricuspid isthmus ablation. 
In the AIT group, 3 (15%) cases showed recovery 
of atrium-pulmonary vein potential conduction: 
2 cases led to AF and 1 case led to atrial tachycardia.
In the control group, AF from SVC was induced 
in 1 (3.33%) case, which was terminated after SVC 
isolation; atrial tachycardia from the gap along the 
PVI ablation line was induced in 2 (6.67%) cases, 
which were terminated after gap ablation; typical 
atrial flutter was induced in 1 case, which was 
treated with tricuspid isthmus ablation. There were 
9 (30%) cases of atrium-pulmonary vein potential 
conduction recovery, in which atrial tachycardia 
was induced in 2 cases, and no atrial arrhythmia 
was induced in 7 cases.
Non-pulmonary vein-related atrial tachyar-
rhythmia was significantly more often induced 
in the AIT group (10 [50%] cases: 5 AF, 3 atrial 
flutter, and 2 atrial tachycardia cases) than in the 
control group (1 AF [3.33%] case). Early but not 
late recurrence rate of atrial tachyarrhythmia was 
significantly higher in the AIT than in the control 
group, with significant differences at every month 
up to 3 months (Table 2).
Before PVI, the levels of thyroid hormones 
were as follows: FT3 (minimum 6.47, maximum 
13.57, average 7.78 ± 1.61 pmol/L), FT4 (mini-
mum 22.53, maximum 60.26, average 30.43 ± 
± 8.23 pmol/L), and TSH (minimum 0.005, maxi-
mum 0.261, average 0.116 ± 0.091 IU/mL). Among 
the 20 patients with AIT, 4 patients with severe 
AIT were treated with methimazole as per endo-
crinologist’s advice after PVI. Thyroid function 
was higher at the time of ablation, and returned to 
normal in 1, 2, and 1 cases at 1, 2, and 3 months 
after PVI, respectively. In other 16 patients who 
did not take the anti-hyperthyroidism drug, thyroid 
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function returned to normal in 10, 4, and 2 cases at 
1, 2, and 3 months after PVI, respectively, which is 
consistent with the report by Bartalena et al. [13] 
who documented that thyroid function returns to 
normal from 1 to 3 months in AIT patients [13–15].
Discussion
In the present study, 20 patients with par-
oxysmal AF complicated with AIT underwent 
radiofrequency ablation therapy to treat frequent 
symptomatic episodes, and as compared to matched 
controls with normal thyroid function, had sig-
nificantly more often isoproterenol-induced AF 
and non-pulmonary vein-related atrial tachyar-
rhythmias, and significantly higher rates of early 
recurrence of atrial tachyaarhythmia.
Higher rates of isoproterenol-induced arrhyth-
mias may be secondary to high thyroid hormone lev-
els, which can: 1) Inhibit the inward L type calcium 
channel, increase the outgoing potassium current, 
shorten the action potential plateau period, and 
Table 1. Comparison of clinical and procedural characteristics between the two studied groups.
AIT group  
(n = 20)
Control group  
(n = 30)
P
Male gender 11 (55%) 17 (56.67%) 0.565
Age [years] 63.65 ± 8.91 60.67 ± 8.54 0.24
Left atrial diameter [cm] 4.29 ± 0.43 4.47 ± 0.32 0.91
Left ventricular end-diastolic dimension [cm] 4.71 ± 0.25 4.47 ± 0.32 0.696
Left ventricular ejection fraction [%] 0.62 ± 0.05 0.64 ± 0.04 0.714
Duration of atrial fibrillation [months] 12.75 ± 12.31 20.07 ± 34.29 0.413
Dose of received amiodarone [mg/d.] 200 200 1
Time of received amiodarone [months] 12.6 ± 7.22 11.35 ± 8.62 0.579
Cases of thyrotoxicosis treated 4 (20%) 0 (0%) –
Operation time [min] 170.60 ± 14.80 158.18 ± 9.06 0.062
X-ray exposure time [min] 16.48 ± 2.15 15.36 ± 1.57 0.058
Success rate of instant pulmonary vein isolation [%] 100% 100% –
Atrial fibrillation induced intraoperatively 7 (35%) 1 (3.33%) 0.005
atypical atrial flutter or atrial tachycardia  
induced intraoperatively
3 (15%) 2 (6.67%) 0.31
Typical atrial flutter induced intraoperatively 3 (15%) 1 (3.33%) 0.17
Non-pulmonary vein-related atrial 
tachyarrhythmias intraoperatively
10 (50%) 2 (6.67%) 0.01
Recovery of conduction of pulmonary vein  
potential induced intraoperatively
3 (15%) 9 (30%) 0.191
Cardiac tamponade 0 (0%) 0 (0%) –
Symptomatic cerebral embolism 0 (0%) 0 (0%) –
Hematoma 1 (5%) 2 (6.67%) 0.651
Data are presented as mean ± standard deviation or n (%); AIT — amiodarone-induced thyrotoxicosis
Table 2. Comparison of early (up to 3 months) 
and late (beyond 3 and up to 12 months) recur-
rence rates after pulmonary vein isolation be-
tween the amiodarone-induced thyrotoxicosis 
(AIT) group and the control group.






1 8 (40%) 4 (13.33%) 0.035
2 9 (45%) 5 (16.67%) 0.032
3 9 (45%) 5 (16.67%) 0.032
Late recurrence
4 4 (20%) 3 (10%) 0.277
5 4 (20%) 3 (10%) 0.277
6 5 (25%) 4 (13.33%) 0.247
7 5 (25%) 5 (16.67%) 0.355
8 5 (25%) 5 (16.67%) 0.355
9 6 (30%) 5 (16.67%) 0.221
10 6 (30%) 5 (16.67%) 0.221
11 6 (30%) 6 (20%) 0.315
12 6 (30%) 7 (23.33) 0.418
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increase the repolarization speed, thereby shorten-
ing action potential duration, effective responding 
period, and reentrant wavelength in the atria, and 
resulting in tiny reentrant waves [16]; 2) Alter 
the atrial distribution of autonomic nerves, cause 
over-allocation of atrial sympathetic nerves and au-
tonomic dysfunction, and increase atrial arrhythmia 
incidence; 3) Significantly increase the autorhyth-
micity of atrial evoked potential [17], causing AF as 
well as atrial flutter and atrial tachycardia.
The abovementioned features also might un-
derlie the higher early recurrence rates of atrial 
tachyarrhytmia in the AIT group, which also might 
be related to local edema after CPVI because of the 
impact of ablation energy on local tissues. Bertag-
lia et al. [18] reported that within 3 months after 
ablation for patients with AF, 46% of patients had 
atrial arrhythmias, most of which spontaneously 
resolved 3 months later.
In order to decrease the recurrence rate of 
AIT patients, we spent more operation time in the 
AIT group (AIT group vs. control group, 170.60 ± 
± 14.80 min vs. 158.18 ± 9.06 min), which may 
result in lower RoC of the pulmonary veins when 
intravenously treated with isoprenaline. Neverthe-
less, no significant difference was found between 
the two groups (p = 0.191). In fact, all patients had 
no RoC of the veins at the moment the operation 
finished. We examined the rate of RoC of the pul-
monary veins during operation, but the recurrence 
rate of atrial tachyarrhythmias in AIT patients 
was examined after operation. During the first 
3 months, we cannot examine the rate of RoC after 
operation, the thyroid hormone levels can affect 
the percentage of recurrence.
Within 3 months, thyroid hormone levels were 
high and normalized thereafter. Thus, the high re-
currence 3 months post ablation was likely due to 
residual mild hyperthyreosis. The thyroid hormone 
levels of both the AIT group and the control group 
were normal after 3 months post ablation, which 
resulted in similar recurrence.
The present study found that after 3 months 
post CPVI, when the thyroid function returned to 
normal, the late success rate was similar in both 
groups. Auer et al. [19] had reported an AF inci-
dence of 13.8% in patients with primary hyperthy-
roidism, and 5 times that of the general population 
in patients with subclinical hyperthyroidism. When 
thyroid function returns to normal, the effects of the 
thyroid hormone on the atria fade away with most 
associated AF resolving [19]. In a previous study, 
for patients with primary hyperthyroidism, after 
thyroid function returned to normal but still had 
AF, ablation success rate was similar to that of AF 
patients without hyperthyroidism [20]. The latter 
result as well as those in the present study indicate 
that after thyroid hormone levels return to normal, 
AF is associated with only focal evoking loci.
In this study, after PVI, the late recurrence 
rate of atrial tachyarrhythmias was lower than early 
recurrence rate, and similar to that of paroxysmal 
AF patients with normal thyroid function. Possible 
reasons for the latter observation include: (1) In 
the AIT group, hyperthyroidism was not very se-
vere, with thyroid function returning to normal in 
both 16 of 20 patients 3 months after amiodarone 
discontinuation or with addition of methimazole for 
3 months in the remaining 4 with more severe AIT; 
(2) Intraoperative isoproterenol via intravenous 
drip induced atrial flutter, AF, and atrial tachycardia 
unrelated to pulmonary vein potential, reducing the 
relapse of atrial arrhythmia after catheter ablation 
[21]; (3) After PVI, observation for 30 min, and iso-
proterenol via intravenous drip, the gap along the 
PVI ablation line was treated with ablation, reducing 
the atrial tachyarrhythmias secondary to recovery 
of atrium-pulmonary vein conduction [21].
Limitations of the study
Interpretation of the findings in the present 
study is limited by its single-center, retrospective 
design with a small sample size and by the fact that 
hyperthyroidism was mild among studied patients 
with paroxysmal AF complicated with AIT. Recur-
rence rates in patients with paroxysmal AF com-
plicated with severe AIT warrant further studies.
Conclusions
For patients with paroxysmal AF complicated 
with AIT, early ablation appears safe and effective 
when performed under the guidance of a 3-dimen-
sional mapping system, with 30 min observation 
and use of isoproterenol and pacing to induce atrial 
tachyarrhythmias related to pulmonary vein and 
extra-pulmonary vein for ablation.
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